Viatris Inc 2024 SR
The report highlights Viatris' progress in 2024, focusing on its mission to provide sustainable access to medicine, reaching approximately 1 billion patients globally. Key achievements include a 19% reduction in Scope 1 and 2 GHG emissions compared to a 2020 baseline and providing 100% of colleagues with access to wellbeing resources. The company supplied over 240 medicines on the WHO Essential Medicines List and donated 174 million doses for humanitarian relief. Viatris also advanced its clinical pipeline with 11 Phase 3 programs and completed strategic divestitures to streamline operations.
Company: Viatris Inc
Sector: Information Information Technology
Country: United States
Year: 2024
Type: SR
Pages: 88
Viatris Inc
Sustainability Report
The report highlights Viatris' progress in 2024, focusing on its mission to provide sustainable access to medicine, reaching approximately 1 billion patients globally. Key achievements include a 19% reduction in Scope 1 and 2 GHG emissions compared to a 2020 baseline and providing 100% of colleagues with access to wellbeing resources. The company supplied over 240 medicines on the WHO Essential Medicines List and donated 174 million doses for humanitarian relief. Viatris also advanced its clinical pipeline with 11 Phase 3 programs and completed strategic divestitures to streamline operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
May 21, 2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees